Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE. IMCIVREE is a precision medicine approved by the FDA for chronic weight management in adults and children aged six and older with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiencies, or Bardet-Biedl syndrome (BBS). The company is also evaluating setmelanotide in Phase II and III trials for treating obesity linked to various MC4R pathway gene variants. The RYTM average annual return since 2017 is shown above.
The Average Annual Return on the RYTM average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RYTM average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RYTM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free RYTM Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
